All In Biotech

Drug Trial Radar · NCT01510028

Multicenter Study of HGT-1110 Administered Intrathecally in Children With Metachromatic Leukodystrophy (MLD)

A Phase I/II Multicenter Open-label Dose Escalation Study of HGT-1110 Administered Intrathecally in Children With Metachromatic Leukodystrophy

Last checked: Nov 20, 2026Latest source record: Jun 14, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

24

Actual

Start

Feb 2, 2012

Primary completion

Jan 20, 2017

Study completion Jan 20, 2017

Sponsor

Lead sponsor
ShireTakeda (TAK)
Sponsor type
Industry
First posted
Jan 13, 2012

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, up to 12 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to determine the safety of ascending doses of HGT-1110 administered by intrathecal (IT) injection for 38 weeks (20 injections) in children with metachromatic leukodystrophy (MLD).

Conditions

  • Metachromatic Leukodystrophy (MLD)

Interventions

  • Recombinant human arylsulfatase ABiological

    6 patients treated with HGT-1110 EOW by IT injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Treatment Emergent Adverse Events (TEAEs) by Type and SeverityTime frame: From start of study treatment up to Week 42
  2. Number of Participants With Clinical Laboratory Abnormalities Reported as Treatment Emergent Adverse Events (TEAEs)Time frame: From start of study treatment up to Week 40
  3. Number of Participants With Vital Sign Abnormalities Reported as Treatment Emergent Adverse Events (TEAEs)Time frame: From start of study treatment up to Week 40
  4. Number of Participants With Electrocardiogram (ECG) Abnormalities Reported as Treatment Emergent Adverse Events (TEAEs)Time frame: From start of study treatment up to Week 40
  5. Number of Participants With Clinically Significant Abnormalities in Physical Examination Reported as Treatment Emergent Adverse Events (TEAE)Time frame: From start of study treatment up to Week 40
  6. Number of Participants With Cerebrospinal Fluid (CSF) Chemistry Abnormalities Reported as Treatment Emergent Adverse Events (TEAEs)Time frame: From start of study treatment up to Week 40
  7. Number of Participants With Positive Anti-SHP611 Antibodies in Cerebrospinal Fluid (CSF) and or SerumTime frame: Baseline up to Week 40

Locations

5 sites in 5 countries. Site status is shown where the registry gives one.

  • The Children's Hospital at Westmead

    Westmead, Australia

  • Rigshospitalet

    Copenhagen, Denmark

  • Hopital de Bicetre

    Le Kremlin-Bicêtre, Île-de-France Region, France

  • Center for Pediatric Clinical Studies

    Tübingen, Baden-Wurttemberg, Germany

  • Osaka University Hospital

    Suita, Japan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.